혈청종양 표지자 CA 125가 극도로 상승한 경계성 난소종양 1예
Extremely elevated serum CA 125 in a borderline tumor of the ovary: A case report
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
경계성 상피성 난소종양은 빈도상 악성종양의 약 10% 정도를 차지한다. 경계성 난소종양은 악성종양과 비교하여 예후가 좋은데 이는 상대적으로 조기에 발견되고 특성상 조직 실질내로 침윤이 없어 보존적인 방법으로도 치유가 가능하기 때문이다. 수술 전 경계성 난소종양과 조기 악성종양을 감별진단하는 것은 중요한데 수술방법에 영향을 미치기 때문이다. 혈청종양 표지자 CA 125는 악성 난소종양의 유용한 진단적 도구이나 경계성 난소종양에서 그 임상적 의미는 아직 확실하지 않다. 저자 등은 경계성 난소종양에서 CA 125 치가 극도로 상승한 예를 수술하고 경과를 관찰하였기에 이를 간단한 문헌고찰과 함께 보고하는 바이다.
Abstract
Tumors of low malignant potential (also called borderline tumors) account for approximately 10% of malignant ovarian neoplasm. Borderline tumors have a much better prognosis and, because they are noninvasive, may be treated less radically than invasive ovarian cancer. The ability to distinguish borderline tumor from early stage malignant disease preoperatively considerably influences surgical treatment, and allows improved counseling of patients. CA 125 is a useful tumor marker in the diagnosis of malignant ovarian tumors. However, in the case of borderline ovarian tumor, the value of CA 125 as a diagnostic tool seems to be invalid. Herein, we report a case of borderline ovarian tumor with extremely elevated serum CA 125 level.
참고문헌 (20)
- Santesson L, "General classification of ovarian tumors. in: Ovarian Cancer", pp.1~8 (1968), Springer-Verlag
- Barakat RR, "Borderline tumors of the ovary", Obstet Gynecol Clin North Am, 21, pp.93~105 (1994)
- Ochiai K, "A retrospective study of 1069 epithelial borderline malignancies of the ovary treated in Japan", Proc Ann Meet Am Soc Clin Oncol, 17, pp.A1429~ (1998)
- Taylor HC, "Malignant and semi-malignant tumors of the ovary", Surg Gynecol Obstet, 48, pp.204~230 (1929)
- Kottmeier HL, "Annual report on surgery for borderline tumor of the ovary : 75 results of treatment in gynecologic cancer. Int Fed Gynecol Obstet", Radiumhemmet (Stockholm), 17, pp.7~10 (1973)
- Serov SF, "International histological classification of tumors. 9", pp.37~38 (1973), World Health Organization
- Tinelli R, "Conservative surgery for borderline ovarian tumors: A review", Gynecol Oncol, 10, pp.185~191 (2006)
- Jones MB, "Borderline Ovarian Tumors: Current Concepts for Prognostic Factors and Clinical Management", Clin Obstet Gynecol, 49, pp.517~525 (2006)
- Link CJ Jr, "Borderline ovarian tumors", Am J Med, 101, pp.217~225 (1996)
- Kaern J, "A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982: A review of clinicopathologic features and treatment modalities", Cancer, 71, pp.1810~1820 (1993)
- Seidman JD, "Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases", Am J Surg Pathol, 20, pp.1331~1345 (1996)
- Rice LW, "Preoperative serum CA-125 levels in borderline tumors of the ovary", Gynecol Oncol, 46, pp.226~229 (1992)
- Gotlieb WH, "CA 125 measurement and ultrasonography in borderline tumors of the ovary", Am J Obstet Gynecol, 183, pp.541~546 (2000)
- Ayhan A, "Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?", Acta Obstet Gynecol Scand, 86, pp.484~490 (2007)
- Makar AP, "Evaluation of serum CA 125 level as a tumor marker in borderline tumors of the ovary", Int J Gynecol Cancer, 3, pp.299~303 (1993)
- Darai E, "Borderline ovarian tumors: a series of 43 patients", Contracept Fertil Sex, 25, pp.933~938 (1997)
- Engelen MJ, "Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors", Gynecol Oncol, 78, pp.16~20 (2000)
- 고재환, "경계성 상피성 난소종양 환자에서 혈청 CA-125농도 측정의 임상적 효용성", 대한산부회지, 37, pp.2073~2080 (1994)
- Ghaemmaghami F, "High levels of CA 125 (over 1,000 IU", ml) in patients with gynecologic disease and no malignant conditions: three cases and literature review, 2007, pp.276, 559~561
- Sevinc A, "Benign causes of increased serum CA-125 concentration", Lancet Oncol, 8, pp.1054~1055 (2007)